These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 4984548)

  • 21. [Experimental evaluation of the antimycobacterial activity of rifampicin].
    Ninni A; Scoles E; Iodice F; Razza I
    Arch Tisiol Mal Appar Respir; 1968 Apr; 23(4):315-28. PubMed ID: 4981410
    [No Abstract]   [Full Text] [Related]  

  • 22. [Results of treatment of experimental tuberculosis in guinea pigs with isoniazid or with isoniazid combined with ethambutol, either in continous or in intermittent regimen].
    Sosnowski W; Rozniecki J; Tomaszkiewicz L; Bechcińska B; Cyperling I
    Gruzlica; 1970 Jan; 38(1):35-42. PubMed ID: 4984432
    [No Abstract]   [Full Text] [Related]  

  • 23. [Experimental study of rifampicin and ethambutol].
    Kozulitsyna TI; Korotaev GA
    Probl Tuberk; 1971; 49(1):64-8. PubMed ID: 5576515
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficacy of rifampicin on experimental mouse tuberculosis].
    Yoshida F
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):35-43. PubMed ID: 4990960
    [No Abstract]   [Full Text] [Related]  

  • 25. [Bacteriologic negation and anatomic development in pulmonary specimens after rifampicin treatment of less than 10 months (10 cases)].
    Constans P; Parrot R; Coury C
    Rev Tuberc Pneumol (Paris); 1970 Jun; 34(4):511-8. PubMed ID: 4994883
    [No Abstract]   [Full Text] [Related]  

  • 26. [Study of the biological characteristics of strains of M. tuberculosis resistant to isoniazid and rifampin].
    Diaconescu C; Iacob L
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1984; 33(2):151-62. PubMed ID: 6093222
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical significance of resistance of Mycobacterium tuberculosis to chemoantibiotics].
    Lucchesi M; Zubiani M; Mancini P; Termine A
    Ann Ist Carlo Forlanini; 1967; 27(3):228-52. PubMed ID: 4972422
    [No Abstract]   [Full Text] [Related]  

  • 28. [Rifampicin resistence and virulence of M. tuberculosis for guinea pigs].
    Schröder KH; Koperska C
    Zentralbl Bakteriol Orig A; 1972 Jan; 219(1):112-3. PubMed ID: 4402403
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of decalcification in the treatment of tuberculosis. 3. The influence of decalcification of the course of experimental tuberculosis in guinea pigs infected with tubercle bacilli of low degree resistance to izoniazid.
    Garapich M; Jelonek A; Kulig A
    Acta Med Pol; 1967; 8(3):313-8. PubMed ID: 4964868
    [No Abstract]   [Full Text] [Related]  

  • 31. [Virulence of rifampicin-resistant tubercle bacilli for experimental animals (preliminary report)].
    Osato T; Shimizu H
    Kekkaku; 1972 May; 47(5):129-34. PubMed ID: 4625370
    [No Abstract]   [Full Text] [Related]  

  • 32. Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.
    Pallanza R; Arioli V; Furesz S; Bolzoni G
    Arzneimittelforschung; 1967 May; 17(5):529-34. PubMed ID: 5631580
    [No Abstract]   [Full Text] [Related]  

  • 33. [Incidence and significance of positive fluorescent bacilloscopy associated with negative cultures during treatment based on isoniazid or rifomycin in tubercular patients treated in the sanatorium].
    Augier J; Parrot R; Gillet P
    Acta Tuberc Pneumol Belg; 1969; 60(3):417-29. PubMed ID: 4984422
    [No Abstract]   [Full Text] [Related]  

  • 34. [Biological characteristics of rifampicin-resistant Mycobacterium tuberculosis].
    Klimenko MT
    Antibiotiki; 1984 Mar; 29(3):185-8. PubMed ID: 6428304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research on the protective action of rifampicin administered intermittently in experimental tuberculosis in guinea pigs].
    Algeorge G; Sibilla S; Rudesco D
    Ann Pediatr (Paris); 1970 Oct; 17(10):674. PubMed ID: 5475418
    [No Abstract]   [Full Text] [Related]  

  • 36. [Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV].
    Grumbach F; Rist N
    Rev Tuberc Pneumol (Paris); 1967; 31(6):749-62. PubMed ID: 4988378
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pathomorphology of experimental tuberculosis induced by rifampicin-resistant mycobacteria].
    Vidin NB; El'shanskaia MP
    Probl Tuberk; 1972; 50(7):63-7. PubMed ID: 4626207
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparative studies on therapeutic effect of rifampicin and isoniazid on experimental mouse tuberculosis (author's transl)].
    Kondo E; Kanai K
    Kekkaku; 1978 Apr; 53(4):261-4. PubMed ID: 661058
    [No Abstract]   [Full Text] [Related]  

  • 39. Rifampicin-susceptibility and rifampicin-resistance in mycobacteria.
    Manten A; van Wijngaarden LJ; van Klingeren B
    Acta Tuberc Pneumol Belg; 1969; 60(3):329-34. PubMed ID: 4984415
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of guinea pigs infected with a mixture of drug resistant and drug sensitive mycobacterium tuberculosis].
    Belogurova VP; Ivanitskaia NN
    Probl Tuberk; 1968; 46(4):69-73. PubMed ID: 4970335
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.